Home / Stock ratings / GLP-1, Obesity and Biotech Stocks / INCY

Stock rating

Incyte Genomics Inc (INCY) Stock Rating & Analysis

As of November 5, 2026, MELANY rates Incyte Genomics Inc 60 out of 100 (Hold). Its highest factor score is earnings track record at 94, and its lowest is catalyst setup at 36.

MELANY ratingRated 2026-11-05

INCY · composite score

60/100
Hold
Nov 5
Rating date
Live price in the app →
Quality53
Momentum63
Risk-adjusted75
Source basis SEC filings and live market dataDated snapshot

Why INCY scores 60/100

INCY's 8 factor scores run from 36 to 94, and 3 of them sit above its composite of 60. Here is how INCY breaks down.

Valuation48/100

Whether the price looks cheap or expensive against earnings, growth, and peers.

  • Forward P/E 13.7x, earnings growth accelerating
Business quality53/100

Margins, returns on capital, and balance-sheet strength.

Price momentum63/100

Direction and relative strength of the recent share-price trend.

  • 50-day MA above 200-day (golden cross zone)
Earnings track record94/100

History of beating or missing estimates, and where estimates are heading.

  • Beat EPS estimates 3 of last 4 quarters
  • Avg EPS beat +18%
Analyst sentiment56/100

What Wall Street price targets and revisions are signalling.

Catalyst setup36/100

Near-term events that could move the stock.

Risk-adjusted profile75/100

Upside weighed against volatility and drawdown risk.

Macro fit50/100

How the current rate and market regime suits this kind of company.

How INCY compares

As of November 20, 2026, Incyte Genomics Inc is tied for 6th of 20 in GLP-1, Obesity and Biotech Stocks, where the average score is 55.

All stock rating pages.

Key risks for INCY

  • Performance partly driven by Healthcare sector, rotation away from this theme would hurt

Sector and theme context

Incyte Genomics Inc sits in the Healthcare sector theme, which MELANY currently rates 99/100 for strength. Theme strength feeds INCY's momentum and catalyst factors above.

Tracking INCY

Incyte Genomics Inc rates Hold right now, so MELANY is not flagging a fresh entry. Add INCY to a watchlist in the app to follow its rating; an alert the moment it changes is part of Pro, free for 30 days.

How MELANY rates INCY

MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Incyte Genomics Inc's 60/100 reflects mature factor weighting for its profile.

Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.

Frequently asked questions about INCY

Is Incyte Genomics Inc (INCY) a buy?

As of 2026-11-05, MELANY rated Incyte Genomics Inc Hold with a composite score of 60/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.

How does INCY rank against similar companies?

As of November 20, 2026, Incyte Genomics Inc is tied for 6th of 20 in MELANY's GLP-1, Obesity and Biotech Stocks list, where the average score is 55. Among the other names in the list, the highest scores belong to REGN (74) and LLY (68).

Should I buy Incyte Genomics Inc stock?

That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Incyte Genomics Inc (INCY) Hold with a composite of 60/100 as of 2026-11-05. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.

What is the INCY stock price forecast?

MELANY does not publish price targets or forecasts for INCY. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 60/100 across eight factors for Incyte Genomics Inc, and re-scores automatically as new price, earnings, and fundamental data arrive. What it does read for INCY as of 2026-11-05: its analyst sentiment factor is 56/100, and its price momentum factor is 63/100.

Is INCY stock overvalued or undervalued?

MELANY's valuation factor currently reads 48/100 for Incyte Genomics Inc, where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives INCY's read.

What price should I buy INCY at?

MELANY is not flagging a fresh entry for INCY at its current Hold rating, so there is no entry zone to publish right now. Add INCY to a watchlist in the app to follow it; an alert the moment the rating changes is part of Pro, free for 30 days.

What are the risks of buying INCY stock?

The top risks MELANY currently flags for Incyte Genomics Inc: Performance partly driven by Healthcare sector, rotation away from this theme would hurt. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.

Is Incyte Genomics Inc a good long-term investment?

For long-term durability the two factors that matter most are business quality, which MELANY scores 53/100 for Incyte Genomics Inc, and earnings track record, at 94/100. The 60/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.

Will INCY stock go up?

Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 63/100 for INCY right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.

How current is this INCY rating?

The rating on this page is a snapshot of MELANY's read as of 2026-11-05, and the score is not recomputed on this page. MELANY re-scores INCY as new price, earnings, and fundamental data arrive; the current rating and the live price are in the app (the rating is part of Pro, free for 30 days).

How this rating works

Market Eyes Live

Every rating graded in public, INCY included

MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.

Get the free iOS app Create a free account on the web Free account, no card. Pro: 30 days free, then $9.99 a month.